VC group funds formation of F-star Alpha with €9.4 million in Series A funding
F-star, an oncology-focused biopharmaceutical company, has formed F-star Alpha with €9.4 million in Series A funding from Atlas Ventures, Aescap Venture, TVM Capital, SR One, MP Healthcare Venture Management and MS Ventures. F-star Alpha has been granted exclusive license to a range of oncology assets.
23 October 2013•3 mins read
